Utilization of GCSF in Metastatic Colorectal Cancer
MEASURE DESCRIPTION
Percentage of Stage 4 colon/rectal cancer patients receiving any white cell growth factors with chemotherapy
Relevance to Value Based Care
ASCO recommendation - do not use white cell stimulating factors for primary prevention of febrile neutropenia for patients with less than 20 percent risk for this complication.
Numerator
Patients ordered GCSF within 30 days following receipt of chemotherapy for metastatic colorectal cancer.
Denominator
Total number of patients with metastatic colorectal cancer receiving chemotherapy within the measurement period.
Exclusion/Exceptions
Patients on clinical trial during measurement period or hospice services received by patient any time during the measurement period
Scoring
Up to 10 points
RESOURCES